- May 01, 2025 Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
- Apr 28, 2025 Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
- Apr 15, 2025 Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
- Mar 25, 2025 Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- Mar 06, 2025 Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
- Feb 25, 2025 Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
- Jan 13, 2025 Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
- Dec 16, 2024 Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
- Nov 12, 2024 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
- Nov 04, 2024 Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
Displaying 21 - 30 of 119